Themis Medicare Q1 FY26: Revenue ₹97.58 Cr, PAT ₹14.22 Cr
Q1 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹98Cr
- −20.7% YoY
- +36.1% QoQ
- Net profit
- −₹14Cr
- Q1 FY25: ₹25 Cr
- Margin
- −10.47%
- −34.2 pp YoY
- +0.3 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Themis Medicare Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q1 FY26 Net Revenue: ₹97.58 Cr, down 20.7% year-on-year from ₹122.99 Cr in Q1 FY25 (Page 8). Q1 FY26 EBITDA: -₹10.08 Cr (negative 10.33% margin), down from ₹29.18 Cr (23.72% margin) in Q1 FY25, representing a 135% YoY decrease.
From Themis Medicare Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1 FY26 Net Revenue: ₹97.58 Cr, down 20.7% year-on-year from ₹122.99 Cr in Q1 FY25 (Page 8).
- Formulation Segment grew 35% quarter-on-quarter in Q1 FY26 (Page 8).
- Revenue from Hospital business expanded 49% quarter-on-quarter in Q1 FY26 (Page 8).
- Revenue from Trade business expanded 165% quarter-on-quarter in Q1 FY26 (Page 8).
- API business showed 52% quarter-on-quarter growth in Q1 FY26 (Page 8).
- Management expects a better bounce back in subsequent quarters with all strategic efforts gaining pace (Page 5).
2 more points from Themis Medicare Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
2 more points from Themis Medicare Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Themis Medicare Ltd said on order book & pipeline — free account, 30 seconds.
Themis Medicare Ltd — Quarterly revenue & net profit
Themis Medicare Ltd Q1 FY26 results — key figures
| ₹ Cr | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 98 | 123 | -20.7% | 72 | +36.1% |
| Operating profit (EBITDA) | -10 | 29 | -135% | -8 | — |
| Operating margin | -10.47% | 23.73% | -34.2 pp | -10.74% | +0.3 pp |
| Profit before tax | -14 | 31 | -144.9% | -11 | — |
| Net profit (PAT) | -14 | 25 | -157.6% | -10 | — |
| EPS (₹) | -1.54 | 2.68 | -157.5% | -1.05 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹90 Cr, net profit ₹7 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Themis Medicare's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- Morepen Laboratories (Q1 FY26)
Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- NGL Fine Chem (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Themis Medicare Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Themis Medicare Ltd Q1 FY26 results?
Q1 FY26 Net Revenue: ₹97.58 Cr, down 20.7% year-on-year from ₹122.99 Cr in Q1 FY25 (Page 8). Q1 FY26 EBITDA: -₹10.08 Cr (negative 10.33% margin), down from ₹29.18 Cr (23.72% margin) in Q1 FY25, representing a 135% YoY decrease.
What is Themis Medicare Ltd share price analysis?
Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
